Roche, Alnylam’s Zilebesiran meets primary endpoint in KARDIA-1 trial
Breaking news in the world of hypertension treatment, Roche and Alnylam Pharmaceuticals have announced the success of their Phase 2 study KARDIA-1. The investigational RNAi therapeutic Zilebesiran met its primary and secondary endpoints in treating adult patients with hypertension. Primary and Secondary Endpoints Achieved Zilebesiran succeeded in significantly reducing systolic blood pressure (SBP) by over […]